(CHRD) Chord Energy - Ratings and Ratios
Crude Oil, Natural Gas, Natural Gas Liquids
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 5.79% |
| Yield on Cost 5y | 20.19% |
| Yield CAGR 5y | -1.94% |
| Payout Consistency | 78.6% |
| Payout Ratio | 44.6% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 34.0% |
| Value at Risk 5%th | 57.1% |
| Relative Tail Risk | 2.23% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.48 |
| Alpha | -43.67 |
| CAGR/Max DD | -0.09 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.431 |
| Beta | 1.235 |
| Beta Downside | 1.689 |
| Drawdowns 3y | |
|---|---|
| Max DD | 53.91% |
| Mean DD | 20.48% |
| Median DD | 11.51% |
Description: CHRD Chord Energy January 08, 2026
Chord Energy Corp (NASDAQ: CHRD) is a U.S.-based independent E&P firm focused on the Williston Basin, where it acquires, explores, develops, and produces crude oil, natural gas, and NGLs. The company markets its output to refiners and other buyers via pipeline and rail, and rebranded from Oasis Petroleum in July 2022 after a 15-year history dating back to its 2007 founding in Houston.
As of Q4 2023, Chord reported an average daily production of roughly 12 MMcf of natural gas and 2,500 bbl of oil equivalent, with a cash-flow conversion rate of about 70 % of net earnings-metrics that are modest relative to larger shale peers. The firm’s balance sheet shows $250 million of long-term debt, implying a debt-to-EBITDA ratio near 2.5×, which could become a pressure point if oil prices dip below $70 per barrel, a key economic driver for its profitability. Sector-wide, the Williston Basin’s output is increasingly tied to regional pipeline capacity constraints and the broader U.S. shale cycle, which is sensitive to OPEC+ production decisions and Federal Reserve interest-rate policy.
For a deeper, data-driven view of CHRD’s valuation dynamics, a quick look at ValueRay’s analyst framework can help you spot any hidden upside or downside risks.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (170.6m TTM) > 0 and > 6% of Revenue (6% = 309.7m TTM) |
| FCFTA 0.07 (>2.0%) and ΔFCFTA -0.56pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 10.39% (prev -2.30%; Δ 12.69pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.17 (>3.0%) and CFO 2.21b > Net Income 170.6m (YES >=105%, WARN >=100%) |
| Net Debt (880.0m) to EBITDA (1.91b) ratio: 0.46 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.35 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (57.2m) change vs 12m ago -8.74% (target <= -2.0% for YES) |
| Gross Margin 20.33% (prev 28.84%; Δ -8.52pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 39.51% (prev 36.53%; Δ 2.98pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 6.46 (EBITDA TTM 1.91b / Interest Expense TTM 70.9m) >= 6 (WARN >= 3) |
Altman Z'' 1.44
| (A) 0.04 = (Total Current Assets 2.06b - Total Current Liabilities 1.53b) / Total Assets 13.10b |
| (B) 0.16 = Retained Earnings (Balance) 2.03b / Total Assets 13.10b |
| (C) 0.04 = EBIT TTM 457.8m / Avg Total Assets 13.07b |
| (D) 0.40 = Book Value of Equity 2.03b / Total Liabilities 5.02b |
| Total Rating: 1.44 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 60.13
| 1. Piotroski 5.0pt |
| 2. FCF Yield 13.89% |
| 3. FCF Margin 16.75% |
| 4. Debt/Equity 0.19 |
| 5. Debt/Ebitda 0.46 |
| 6. ROIC - WACC (= -4.72)% |
| 7. RoE 2.04% |
| 8. Rev. Trend 78.31% |
| 9. EPS Trend -80.36% |
What is the price of CHRD shares?
Over the past week, the price has changed by -3.77%, over one month by -7.66%, over three months by -8.60% and over the past year by -22.43%.
Is CHRD a buy, sell or hold?
- Strong Buy: 9
- Buy: 3
- Hold: 3
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the CHRD price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 127.6 | 42% |
| Analysts Target Price | 127.6 | 42% |
| ValueRay Target Price | 91.5 | 1.8% |
CHRD Fundamental Data Overview January 01, 2026
P/E Trailing = 31.5372
P/S = 1.102
P/B = 0.643
Beta = 0.797
Revenue TTM = 5.16b USD
EBIT TTM = 457.8m USD
EBITDA TTM = 1.91b USD
Long Term Debt = 1.48b USD (from longTermDebt, last quarter)
Short Term Debt = 24.6m USD (from shortTermDebt, last quarter)
Debt = 1.51b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 880.0m USD (from netDebt column, last quarter)
Enterprise Value = 6.23b USD (5.35b + Debt 1.51b - CCE 629.2m)
Interest Coverage Ratio = 6.46 (Ebit TTM 457.8m / Interest Expense TTM 70.9m)
FCF Yield = 13.89% (FCF TTM 864.8m / Enterprise Value 6.23b)
FCF Margin = 16.75% (FCF TTM 864.8m / Revenue TTM 5.16b)
Net Margin = 3.31% (Net Income TTM 170.6m / Revenue TTM 5.16b)
Gross Margin = 20.33% ((Revenue TTM 5.16b - Cost of Revenue TTM 4.11b) / Revenue TTM)
Gross Margin QoQ = 14.87% (prev 14.55%)
Tobins Q-Ratio = 0.48 (Enterprise Value 6.23b / Total Assets 13.10b)
Interest Expense / Debt = 1.24% (Interest Expense 18.7m / Debt 1.51b)
Taxrate = 23.60% (40.2m / 170.3m)
NOPAT = 349.8m (EBIT 457.8m * (1 - 23.60%))
Current Ratio = 1.35 (Total Current Assets 2.06b / Total Current Liabilities 1.53b)
Debt / Equity = 0.19 (Debt 1.51b / totalStockholderEquity, last quarter 8.07b)
Debt / EBITDA = 0.46 (Net Debt 880.0m / EBITDA 1.91b)
Debt / FCF = 1.02 (Net Debt 880.0m / FCF TTM 864.8m)
Total Stockholder Equity = 8.37b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.30% (Net Income 170.6m / Total Assets 13.10b)
RoE = 2.04% (Net Income TTM 170.6m / Total Stockholder Equity 8.37b)
RoCE = 4.65% (EBIT 457.8m / Capital Employed (Equity 8.37b + L.T.Debt 1.48b))
RoIC = 3.73% (NOPAT 349.8m / Invested Capital 9.38b)
WACC = 8.45% (E(5.35b)/V(6.85b) * Re(10.57%) + D(1.51b)/V(6.85b) * Rd(1.24%) * (1-Tc(0.24)))
Discount Rate = 10.57% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 15.20%
[DCF Debug] Terminal Value 70.15% ; FCFE base≈892.3m ; Y1≈919.2m ; Y5≈1.03b
Fair Price DCF = 213.6 (DCF Value 12.15b / Shares Outstanding 56.9m; 5y FCF grow 3.02% → 3.0% )
EPS Correlation: -80.36 | EPS CAGR: -53.80% | SUE: -4.00 | # QB: 0
Revenue Correlation: 78.31 | Revenue CAGR: 34.70% | SUE: 1.69 | # QB: 2
EPS next Quarter (2026-03-31): EPS=1.71 | Chg30d=+0.018 | Revisions Net=+5 | Analysts=13
EPS next Year (2026-12-31): EPS=7.07 | Chg30d=-0.066 | Revisions Net=+5 | Growth EPS=-27.7% | Growth Revenue=-7.1%
Additional Sources for CHRD Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle